Full-Length TFPI Release by Heparinoid Sulodexide

Borawski J. , Dubowski M. , Rydzewska-Rosolowska A. , Mysliwiec M. Intravenous and oral sulodexide versus coagulation activation markers in humans . Clin Appl Thromb Hemost. IN PRESS.

Borawski J. , Dubowski M. , Pawlak K. , Mysliwiec M. Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers. Clin Appl Thromb Hemost. 2008; DOI: 10.1177/1076029608326170.

Gozdzikiewicz J. , Borawski J. , Mysliwiec M. Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost. 2009;15(1):92-97.

Borawski J. , Dubowski M. , Pawlak K. , Mysliwiec M. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007;558(1-3):167-171.

Sandset PM , Abildgaard U. , Larsen ML Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988;50(6):803-813.

Hoppensteadt DA , Walenga JM , Fasanella A. , Jeske W. , Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res. 1995;77(2):175-185.

Lupu C. , Poulsen E. , Roquefeuil S. , Westmuckett AD , Kakkar VV , Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1999;19(9):2251-2262.

Hansen JB , Sandset PM , Huseby KR , Huseby NE , Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost. 1996;76(5):703-709.

Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998;18(1):1-20.

Abaterusso C. , Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol . 2006;5:211-222.

Lauver DA , Lucchesi BR Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006;24(3-4):214-226.

Linhardt RJ , al- Hakim A. , Liu JA , et al. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol. 1991;42(8):1609-1619.

Nenci GG Dermatan sulphate as an antithrombotic drug. Pathophysiol Haemost Thromb. 2002;32(5-6):303-307.